Clinical significance and biological function of miR-3613-3p in glioma

Gliomas are a prevalent form of brain tumor with broad invasion, which has a worse prognosis and the survival rate. This study aims to investigate the clinical significance of miR-3613-3p in glioma patients.

We collected blood samples from 84 glioma patients and 84 healthy controls for further analysis. The expression levels of miR-3613-3p were evaluated using RT-qPCR. Kaplan-Meier methods were used to assess overall survival, and we used multivariate Cox proportional hazards regression analysis to assess the prognostic factors. Apoptosis was evaluated through flow cytometry and the MTT assay measured the proliferation. The results of the dual-luciferase reporter assay were evidence for the relationship between miR-3613-3p and EphA7.

Kaplan-Meier analysis indicated that patients with low expression levels of miR-3613-3p exhibited a poorer prognosis compared to those with high expression levels. Multivariate Cox proportional hazards regression analysis confirmed that miR-3613-3p expression was associated with glioma patient prognosis. MiR-3613-3p inhibited proliferation and promoted apoptosis in glioma cells. MiR-3613-3p negatively regulated EphA7 expression levels, and overexpressing miR-3613-3p reversed the reduction of the apoptosis rate and increase of cell proliferation caused by overexpression of EphA7.

In this research, we identified that high expression levels of miR-3613-3p were associated with a better prognosis and EphA7 was negatively regulated by miR-3613-3p to inhibit the development of glioma.